Post Archives

Visitor Survey

Visitor Survey

labile diabetes

Link: Two patients with Hashimoto’s encephalopathy and uncontrolled diabetes successfully treated with levetiracetam

Abstract:

Hashimoto’s encephalopathy (HE) is a rare syndrome of progressive or relapsing–remitting encephalopathy associated with elevated serum anti-thyroid antibody concentrations. It is thought to be an autoimmune process that generally responds well to high-dose corticosteroids and other immunomodulatory therapies. However, some patients are unresponsive to steroids or are unable to receive immune therapy. A viable alternative is needed for this group. Given that seizure and EEG abnormalities are commonly associated with this syndrome, we postulate that treatment with levetiracetam, which has duel anti-inflammatory and anti-seizure mechanisms, might show clinical benefit. We present the cases of two patients who met the criteria for HE but were unable to receive steroids due to labile diabetes. They were both successfully treated with levetiracetam.

The text may be found at http://www.sciencedirect.com/science/article/pii/S0022510X14007217. However, you may need to purchase access or have a membership to read the full study at Science Direct.

Copyright © 2014 Published by Elsevier B.V. | Journal of the Neurological Sciences

 

This website is not a substitute for independent professional advice. Nothing contained in this site is intended to be used as medical advice. No articles, personal accounts, or other content are intended to be used to diagnose, treat, cure or prevent any disease, nor should it be used for therapeutic purposes or as a substitute for your own health professionals advice.